Kelly Anne is a deputy editor at Forbes Advisor overseeing the development of various initiatives, including newsletters, social media, and new content verticals. Previously, she worked as a senior ...

The FDA has approved Otarmeni, the first-ever gene therapy for genetic hearing loss caused by the OTOF gene, for both pediatric and adult patients after positive results.

The US Food and Drug Administration on Thursday approved the first gene therapy for inherited hearing loss, a one-time treatment that proved to be life-changing for a small number of children in a ...

Regeneron Pharmaceuticals Inc. will offer a gene therapy that restored hearing for a small number of profoundly deaf children at no cost after US regulators approved the treatment.

Researchers say a gene therapy allowed deaf children and adults as old as 32 to hear for the first time. The benefits have persisted for more than two years for some patients.

Five children who were born completely deaf have had some reversal of hearing loss after receiving a "groundbreaking" gene therapy. The clinical trial, which was co-led by Mass Eye and Ear in Boston ...

The treatment, developed by Regeneron Pharmaceuticals, is for a very rare form of deafness. But it represents a medical milestone.

Hearing loss is the reduced ability to hear sounds compared to someone with normal hearing. Sensorineural hearing loss is the result of damage to the inner ear nerves. Conductive hearing loss is the ...

Investigators analyzed the prevalence of hearing/vestibular problems, racial differences, and relationships to physical function in breast cancer survivors.

On April 23, the Food and Drug Administration approved the first-ever gene therapy for a rare, congenital form of deafness. The treatment’s maker, biotechnology company Regeneron, says it plans to ...